|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
|
8941669 |
1996 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results support the hypothesis that (1) primary cutaneous CD30+ LPDs (including LyP) and primary nodal ALCL are distinct diseases that differ in clinical behavior and pathogenesis and (2) differential expression of t(2;5) can help to distinguish between primary cutaneous CD30+ LPDs and ALCL of nodal origin.
|
8605362 |
1996 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Several primary cutaneous lymphoproliferative disorders and Hodgkin's disease are also known to contain CD30+ large lymphoid cells.
|
8781433 |
1996 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This points to a molecular aetiology of primary cutaneous ALC lymphomas and LyP distinct from that of extracutaneous CD30+ lymphoproliferative disease.
|
9415224 |
1997 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
|
9347791 |
1997 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.
|
9449486 |
1997 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Additional studies will be needed to determine if t(2;5) status has any clinical significance for patients with CD30+ primary cutaneous lymphoproliferative disorders.
|
9638979 |
1998 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, primary cutaneous CD30+ lymphoproliferative disorders form a heterogeneous spectrum including anaplastic large cell lymphomas, the majority of which display a good prognosis.
|
10955685 |
2000 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The CD30 (Ki-1)-positive lymphoproliferative disorders show a non-epidermotropic infiltrate of large-sized pleomorphic T cells, being extremely rare those that develop from B cells.
|
11972717 |
2002 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive.
|
15133473 |
2004 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The lesions in these patients seem to be the oral counterpart of the spectrum of primary cutaneous CD30+ lymphoproliferative disorders and should be recognized as such to avoid a diagnosis of large T-cell lymphoma and possible consequent overtreatment.
|
14750239 |
2004 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, differences in the classification of cutaneous T-cell lymphomas other than mycosis fungoides, Sezary syndrome, and the group of primary cutaneous CD30+ lymphoproliferative disorders and the classification and terminology of different types of cutaneous B-cell lymphomas have resulted in considerable debate and confusion.
|
15692063 |
2005 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that allele-specific differences in the control of CD30 transcription may determine the pathogenesis of the spectrum of CD30+ cutaneous lymphoproliferative disorders.
|
15894695 |
2005 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
|
17083688 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The current clinicopathologic classification of CD30+ cutaneous lymphoproliferative disorders is insufficient.
|
17387297 |
2007 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A few recent case reports have demonstrated molecular evidence of T-cell clonality in TUGSE and CD30 immunoreactivity in the large atypical mononuclear cells, raising the possibility that a TUGSE subset may represent the oral counterpart of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
|
19846813 |
2009 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Systemic anaplastic large cell lymphoma (ALCL) involving the skin should be differentiated from primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
19091487 |
2009 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis (LyP) is a recurrent, self-healing eruption belonging to the spectrum of cutaneous CD30+lymphoproliferative disorders.
|
20661014 |
2010 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic large cell cutaneous lymphomas are clinically and pathologically heterogeneous, CD30 + (Ki-1) lymphoproliferative disorders.
|
22565437 |
2012 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ lymphoproliferative disorders of the skin: still an open question.
|
23149700 |
2012 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis (LyP) belongs to the spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.
|
23026936 |
2013 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
22773605 |
2013 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a diagnosis of lymphoma is established, it is important to exclude systemic anaplastic lymphoma kinase-negative ALCL involving the breast, primary cutaneous ALCL, and other CD30(+) lymphoproliferative disorders.
|
24878027 |
2014 |